Protective effect of Jinghua Weikangjiao Pill on gastric and small intestinal mucosal damage induced by platelet drugs

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000030063

Enrollment

Unknown

Registered

2020-02-22

Start date

2020-03-01

Completion date

Unknown

Last updated

2020-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ntiplatelet drug-induced gastric and small intestinal mucosal injury

Interventions

Group A:Jing-Hua Wei-Kang

Group B:Proton pump inhibitor

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >=18 years male or female; 2. those who plan to take antiplatelet drugs; 3. those who agree to undergo capsule endoscopy before and after treatment; 4. those who have negative 13C-Hp breath test; 5. Those who have not taken other drugs that can cause stomach upset; 6. Have the ability to give informed consent, can adhere to the visit plan of this study, and can complete all study evaluations.

Exclusion criteria

Exclusion criteria: 1. Contraindications for capsule endoscopy (patients with suspected digestive tract stenosis, patients with a history of abdominal surgery); 2. Patients who refuse to undergo Helicobacter pylori-related examination and treatment; 3. Peptic ulcer, digestion Patients with gastrointestinal bleeding and other digestive diseases; 4. Patients with acute cerebrovascular disease, acute myocardial infarction, trauma, infection, suspected or confirmed diseases such as malignant tumors and hematological disorders; 5. taken within 4 weeks PPI, H2RA, antibiotics or gastric mucosal protective agents; 6. those who are treated with drugs such as glucocorticoids, warfarin, heparin; 7. severe liver and kidney damage, blood, endocrine and other diseases; 8. pregnant women And pregnant or lactating women; 9. those with mental illness or severe neurosis, who cannot express subjective symptoms, who do not follow the doctor's advice during treatment, and who cannot guarantee that the medication is completed as required during the trial; 10. those who refuse or cannot accept.

Design outcomes

Primary

Measure	Time frame
Capsule endoscopy score;	—

Countries

China

Contacts

Public ContactJiangbn Wang

Department of Gastroenterology, China-Japan Union Hospital of Jilin University

zrlwangjb@medmail.com.cn+86 13578993125

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026